DelveInsight's 'Myotonic Dystrophy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline myotonic ...

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences ...

If you’re on the fence about investing in Organon & Co., Harmony Biosciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...

If you’re on the fence about investing in Jazz Pharmaceuticals plc, Harmony Biosciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Harmony Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.43, meaning that its share price is ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has already been able to receive FDA approval for its drug known as WAKIX [PITOLISANT]. It is for excessive daytime sleepiness [EDS] or cataplexy ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that its Board of Directors authorized the repurchase of up to $125 million of the Company's common stock. "Our... Harmony Biosciences ...

On Thursday, Raymond James resumed coverage on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) with a positive outlook, assigning the stock an Outperform rating and setting a price target of $40.00.

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings ...

根据最近的SEC文件显示，Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)的董事Antonio Gracias已出售了公司大量股票。这些交易发生在11月1日和11月5日，涉及以每股30.3025美元的价格出售460万股，总计约1.394亿美元。在这些出售之后，Gracias及相关实体现持有Harmony Biosciences ...

Harmony Biosciences has reported a strong financial performance for the fourth quarter and full year of 2023, with significant revenue growth driven by its narcolepsy treatment,... On Thursday ...